Business Description
20/20 Biolabs Inc
NAICS : 423450
SIC : 5047
ISIN : US90138K1016
Total Employee Number:
14Description
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.93 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -9.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -4.25 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 66.19 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.8 | |||||
9-Day RSI | 64.67 | |||||
14-Day RSI | 54.97 | |||||
3-1 Month Momentum % | -54.54 | |||||
6-1 Month Momentum % | -96.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.99 | |||||
Quick Ratio | 1.95 | |||||
Cash Ratio | 1.78 | |||||
Days Inventory | 25.28 | |||||
Days Sales Outstanding | 37.08 | |||||
Days Payable | 228.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 31.52 | |||||
Operating Margin % | -215.69 | |||||
Net Margin % | -285.05 | |||||
EBITDA Margin % | -247.65 | |||||
FCF Margin % | -137.5 | |||||
OCF Margin % | -136.86 | |||||
ROE % | -520.71 | |||||
ROA % | -120.51 | |||||
ROIC % | -182.06 | |||||
ROC (Joel Greenblatt) % | -806.14 | |||||
ROCE % | -210.83 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.69 | |||||
PB Ratio | 4.2 | |||||
Price-to-Tangible-Book | 6.16 | |||||
EV-to-EBIT | -0.61 | |||||
EV-to-Forward-EBIT | -0.67 | |||||
EV-to-EBITDA | -0.61 | |||||
EV-to-Revenue | 1.52 | |||||
EV-to-Forward-Revenue | 1.05 | |||||
EV-to-FCF | -1.11 | |||||
| Price-to-Net-Current-Asset-Value | 11.09 | |||||
Earnings Yield (Greenblatt) % | -163.93 | |||||
FCF Yield % | -39.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AIDX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
20/20 Biolabs Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.04 | ||
| EPS (TTM) ($) | -0.746 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 54.97 | ||
| 14-Day ATR ($) | 0.059289 | ||
| 20-Day SMA ($) | 0.473213 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.4011 - 50 | ||
| Shares Outstanding (Mil) | 12.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
20/20 Biolabs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
20/20 Biolabs Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 98 days | ||
| General meeting for 2026 | 2026-08-18 10:00 | 0.55 (+0.07%) | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 0.52 (+13.50%) | ||
| 20/20 BioLabs Monthly Investor Webinar | 2026-08-05 12:00 | 0.46 (+3.64%) | ||
| Sidoti Virtual Micro-Cap | 2026-05-20 15:15 | 1.34 (+1.93%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 1.34 (+1.93%) | ||
| Annual report for 2025 | 2026-03-31 | 1.78 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 1.78 (+0.00%) |
Show
Entries
20/20 Biolabs Inc Frequently Asked Questions
What is 20/20 Biolabs Inc(AIDX)'s stock price today?
The current price of AIDX is $0.55. The 52 week high of AIDX is $50.00 and 52 week low is $0.40.
When is next earnings date of 20/20 Biolabs Inc(AIDX)?
The next earnings date of 20/20 Biolabs Inc(AIDX) is 2026-11-30 Est..
Does 20/20 Biolabs Inc(AIDX) pay dividends? If so, how much?
20/20 Biolabs Inc(AIDX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on 20/20 Biolabs Inc
Headlines
See More- 1
Aug 17, 2026
20/20 Biolabs Q2 GAAP EPS of -$0.26, revenue of $0.73M
Seeking Alpha • 10:06am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers